|
|
Drugs of Tomorrow 2000: Arthritis - Developments For a Competitive MarketPublished by: Datamonitor Published: Apr. 1, 2001 - 251 Pages Table of ContentsTABLE OF CONTENTS EXECUTIVE SUMMARY Report summary Introduction Patient potential in arthritis Unmet needs in arthritis Investors in arthritis Class focus Future market leaders R&D opportunities in arthritis DISEASE OVERVIEW Definition of disease Classification of disease Rheumatoid arthritis The prevalence of rheumatoid arthritis Osteoarthritis The prevalence of osteoarthritis Classification of pipeline products NSAIDs DMARDs Opioids Clinical endpoints in arthritis ACR values Pain scales Unmet needs in arthritis Improved efficacy Disease reversal and cure Improved side effects Improved delivery Cost of treatment Earlier diagnosis Compliance Increased awareness ARTHRITIS PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in arthritis Key R&D protocol strategies in arthritis Key drug delivery strategies in arthritis Key licensing strategies in arthritis Pipeline analysis by class Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company DRUG ANALYSIS NSAIDs Key Valdecoxib MK-663 ML-3000 T-614 JTE-522 COX 189 CI-1004 Phase I NSAIDs NO-NSAIDs DMARDs - TNF-a Blockade D2E7 CDP-870 SR31747 sTNF-RI rhTBP VX-745 DMARDs - T cell targeted Tacrolimus 4162W94 Pentostatin Clenoliximab HuMax-CD4 DMARDs - Non-TNF-a cytokine targeted IL-1ra rHuIL-10 VX-740 INF-ß TRK-530 DMARDs - Vaccines IR-501 AnervaX.RA LeukoVAX AnergiX.RA DMARDs - Others KE-298 CBF-BS2 5G1.1 DW-166HC DMP777 DMARDs - Phase I MDX-CD4 AGT-1 Atiprimod ZD2315 ZD7349 D1927 BB-2827 Micellar paclitaxel ABX-IL-8 CI-1018 MX-68 Opioids Dirame Transfenta (E-Trans fentanyl) Asimadoline LEF/BCH-3963 Morphine Moraxen Morphelan DepoMorphine AERx morphine TDS morphine Patient potential for morphine formulations Satisfaction of unmet needs Combination therapies Novel drugs class Cizolirtine Epibatidine (ABT-594) ZD 6416 Cholecystokinin (CCK) antagonists Key phase I analgesics CGX-II Neurotrophin 3 Key preclinical/research development projects Enkephalins Cannabinoids Kappa opioid receptor agonists Recently discontinued projects P54 MorphiDex (morphine sulfate + dextromethorphan) COMPARATIVE ANALYSIS Comparison of classes Comparative analysis of the opioid drug class Comparison of drug delivery method in the opioid drug class Comparison of side effects in the opioid drug class Comparison of marketing strength in the opioid drug class DMARD comparison by sub-class Efficacy Side effects Drug delivery Marketing strength Comparative analysis of TNF-a blockade drugs Comparison of efficacy in TNF-a blockade drugs Comparison of side effects in TNF-a blockade drugs Comparison of drug delivery in TNF-a blockade drugs Comparison of marketing strength in TNF-a blockade drugs Comparative analysis of T cell targeted drugs Comparison of efficacy in T cell targeted drugs Comparison of side effects in T cell targeted drugs Comparison of drug delivery in T cell targeted drugs Comparison of marketing strength in T cell targeted drugs Comparative analysis of Non-TNF-a cytokine targeted drugs Comparison of efficacy in non-TNF-a targeted drugs Comparison of side effects in non-TNF-a targeted drugs Comparison of drug delivery in non-TNF-a targeted drugs Comparison of marketing strength in non-TNF-a targeted drugs Comparative analysis of vaccines Comparison of efficacy in vaccines Comparison of side effects in vaccines Comparison of drug delivery in vaccines Comparison of marketing strength in vaccines Comparative analysis of 'Others' class Comparison of efficacy in 'Others' class drugs Comparison of side effects in 'Others' class drugs Comparison of drug delivery in 'Others' class drugs Comparison of marketing strength in 'Others' class drugs NSAID comparison Efficacy Side effects Drug delivery Marketing strength FUTURE FOCUS IN ARTHRITIS Future trends in the incidence and prevalence of arthritis Osteoarthritis Rheumatoid arthritis Prospective drug launches in arthritis Launch forecast methodology Forecast launches in arthritis from 2000 to 2007 Market forecasts, 2000-2007 Forecast methodology Arthritis Market Forecasts Factors influencing the arthritis market, 2000-2007 Trends in the global arthritis market to 2007 Arthritis drug class forecast Factors influencing the DMARDs class to 2007 Factors influencing the NSAIDs class to 2007 Factors influencing the opioid class to 2007 Factors influencing the opioid combinations class to 2007 Factors influencing the non-opioids class to 2007 Trends in the arthritis drug class market Key R&D product forecasts NSAID pipeline product forecasts to 2007 DMARD pipeline product forecasts to 2007 Opioid pipeline product forecasts to 2007 Opioid combination pipeline product forecasts to 2007 Long term potential of phase I and pre-clinical compounds Specific opioid receptor agonists Gene therapy APPENDICES Forecasting drug launches for drugs in development Global highest stage of development Reclassification of development phases Primary delivery classifications List of tables List of figures (c) Datamonitor 2000. All Rights Reserved. AbstractCurrently, a significant number of products are in development for the treatment of arthritis and arthritis-associated pain. Datamonitor expects this will lead to a saturation of the market over the next seven years as drugs with similar modes of action compete for a share of a patient population that is not expected to expand to meet the available supply of treatments. Competition within this market looks set to increase dramatically. Drugs of Tomorrow 2000: Arthritis provides an in-depth analysis of the arthritis pipeline products and forecasts their performance to 2007. The report provides comprehensive coverage of all phase II and phase III treatments under development to treat rheumatoid arthritis and osteoarthritis, and the pain associated with these conditions. Also, the current and future commercial attractiveness of these drugs is assessed.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||